AstraZeneca PLC's (LON:AZN) rather patchy success rate for late-stage clinical trials continued after its drug Fasenra failed to show a statistically significant impact on people suffering exacerbations of moderate to very severe chronic obstructive pulmonary disease (COPD).
The top-line results from the TERRANOVA phase III study followed the announcement earlier this month that another final-phase assessment of the treatment, called, GALATHEA, had drawn a blank.
READ: AstraZeneca receives more solid data for its Imfinzi lung cancer treatment
Chief medical officer Dr Sean Bohen said: "These results are disappointing because uncontrolled COPD patients already on dual or triple inhaled therapy need new treatment options.
"We will now analyse the complete data sets from the GALATHEA and TERRANOVA trials to further understand these results."